Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avidity Biosciences ( (RNA) ) has provided an update.
On July 23, 2025, Avidity Biosciences announced that the FDA granted Breakthrough Therapy designation to delpacibart zotadirsen for treating Duchenne muscular dystrophy in patients with mutations amenable to exon 44 skipping. Avidity plans to submit a Biologics License Application for this therapy by the end of 2025, which could significantly impact its operations and market positioning.
The most recent analyst rating on (RNA) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
Avidity Biosciences’ overall score reflects significant corporate developments with positive trial results, offset by financial struggles with profitability and cash flow. Technical indicators are neutral, while valuation challenges are typical for a biotech company in its growth phase.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences operates in the biotechnology industry, focusing on developing therapies for genetic disorders. The company specializes in creating innovative treatments for conditions like Duchenne muscular dystrophy, with a market focus on genetic mutations.
Average Trading Volume: 1,617,812
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.04B
For a thorough assessment of RNA stock, go to TipRanks’ Stock Analysis page.